Resource Type

Journal Article 207

Year

2023 5

2022 17

2021 21

2020 16

2019 19

2018 20

2017 20

2016 8

2015 11

2014 10

2013 6

2012 14

2011 3

2010 4

2009 9

2008 3

2007 8

2006 2

2004 2

2003 2

open ︾

Keywords

cancer immunotherapy 3

Biomarkers 2

CAR T cells 2

Cancer 2

Treg 2

characterization 2

chimeric antigen receptor T cell 2

cogeneration 2

free vibration analysis 2

hepatocellular carcinoma 2

immunotherapy 2

meta-heuristic algorithm 2

passenger car 2

(PFOA) 1

1 1

1T/2H-MoS2 1

21) 1

21) AML 1

21)(q22 1

open ︾

Search scope:

排序： Display mode:

CAR T-cell immunotherapy: a powerful weapon for fighting hematological B-cell malignancies

Frontiers of Medicine 2021, Volume 15, Issue 6,   Pages 783-804 doi: 10.1007/s11684-021-0904-z

Abstract: Chimeric antigen receptor T-cell (CAR T) immunotherapy opens a new path for targeted therapy of hematologicalIn this review, through a representative case study, we summarize the current experience of CAR T-celleffects, the causative mechanisms of therapy resistance, and new strategies to improve the efficacy of CART-cell therapy.

Keywords： CAR T cells     hematological malignancies     review    

HTML PDF Collect

CRISPR-Cas9 mediated LAG-3 disruption in CAR-T cells

Yongping Zhang, Xingying Zhang, Chen Cheng, Wei Mu, Xiaojuan Liu, Na Li, Xiaofei Wei, Xiang Liu, Changqing Xia, Haoyi Wang

Frontiers of Medicine 2017, Volume 11, Issue 4,   Pages 554-562 doi: 10.1007/s11684-017-0543-6

Abstract:

T cells engineered with chimeric antigen receptor (CAR) have been successfully applied to treat advancedThe immunosuppressive nature of tumor microenvironment is considered one of the key factors limiting CAR-TWe successfully generated LAG-3 knockout T and CAR-T cells with high efficiency using LAG-3 knockout CAR-T cells displayed robust antigen-specific antitumor activity incell culture and in murine xenograft model, which is comparable to standard CAR-T cells.

Keywords： CAR-T     CRISPR-Cas9     LAG-3    

HTML PDF Collect

Programming CAR T cells to enhance anti-tumor efficacy through remodeling of the immune system

Xiaohui Wang, Zhiqiang Wu, Wei Qiu, Ping Chen, Xiang Xu, Weidong Han

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 726-745 doi: 10.1007/s11684-020-0746-0

Abstract: Chimeric antigen receptor (CAR) T cells have been indicated effective in treating B cell acute lymphoblasticHowever, CAR T cells have achieved minimal success against solid malignancies because of the additionalIn this review, we focus on the recent advances in the engineering of CAR T cell therapies to restorethe immune response in solid malignancies, especially with CAR T cells acting as cellular carriers tothe anti-tumor outcomes of CAR T cell therapies in solid tumors.

Keywords： CAR T cells     immunoregulatory molecules     endogenous immune response     solid malignancies    

HTML PDF Collect

Chimeric antigen receptor T cell therapies for acute myeloid leukemia

Bin Gu, Jianhong Chu, Depei Wu

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 701-710 doi: 10.1007/s11684-020-0763-z

Abstract: Abstract Chimeric antigen receptor T cell (CAR T) therapies have achieved unprecedented efficacy in B-cellAlthough the identification of an ideal target antigen for AML is challenging, CAR T therapy remainsIn this review, we focus on the most recent and promising advances in CAR T therapies for AML.

Keywords： acute myeloid leukemia     CAR T     immunotherapy    

HTML PDF Collect

Chimeric Antigen Receptors and Regulatory T Cells: The Potential for HLA-Specific Immunosuppression in Review

Sabrina Wright, Conor Hennessy, Joanna Hester, Fadi Issa

Engineering 2022, Volume 10, Issue 3,   Pages 30-43 doi: 10.1016/j.eng.2021.10.018

Abstract: to a predefined target by the inclusion of an antigen-specific binding region within the synthetic CARIn contrast to conventional T cells (Tconvs), regulatory T cells (Tregs) play a major role in suppressingCAR expression within Tregs has been proposed as a therapy for autoimmune and inflammatory diseases,This review examines the rationale behind the development of CAR-Tregs, their significance for humantransplantation, potential designs, safety considerations, and comparisons of CAR-Tregs in transplantation

Keywords： Chimeric antigen receptors     T cell     Treg     Alloimmunity     Bioengineering     Transplant     Autoimmunity    

HTML PDF Collect

CAR T cells redirected against tumor-specific antigen glycoforms: can low-sugar antigens guarantee a

Frontiers of Medicine 2022, Volume 16, Issue 3,   Pages 322-338 doi: 10.1007/s11684-021-0901-2

Abstract: To date, six chimeric antigen receptor T cell (CAR-T) therapies have been permitted for the treatmentHowever, several clinical trials of solid tumor CAR-T therapies were prematurely terminated, or theyaberrantly glycosylated glycoforms of tumor-associated antigens can also minimize the off-tumor effects of CAR-TTn, T, and sialyl-Tn antigens have been reported to be involved in tumor progression and metastasis,discuss how underglycosylated antigens emerge and then detail the latest advances in the development of CAR-T-based

Keywords： cancer immunotherapy     chimeric antigen receptor     solid tumors     tumor-associated antigen     glycosylation     O-glycans     adoptive cell therapy    

HTML PDF Collect

exosomes induce initial activation by exosomal CD19 antigen but impair the function of CD19-specific CART-cells via TGF-β signaling

Frontiers of Medicine doi: 10.1007/s11684-023-1010-1

Abstract: exosomes induce initial activation by exosomal CD19 antigen but impair the function of CD19-specific CART-cells via TGF-β signaling

Keywords： exosomes induce activation     impair function CD19     exosomal CD19 antigen    

HTML PDF Collect

Quality Control and Nonclinical Research on CAR-T Cell Products: General Principles and Key Issues Review

Yonghong Li, Yan Huo, Lei Yu, Junzhi Wang

Engineering 2019, Volume 5, Issue 1,   Pages 122-131 doi: 10.1016/j.eng.2018.12.003

Abstract:

Adoptive cell therapy using chimeric antigen receptor T (CAR-T) cells, which is a promising cancerCAR-T cells are genetically modified T cells that can specifically recognize tumor specific antigensAt present, exciting results are being achieved in clinical applications of CAR-T cells for patientsThe research and development of CAR-T cells for various targets and for the treatment of solid tumorsthe general principles of and key issues regarding the quality control and nonclinical research of CAR-T

Keywords： Chimeric antigen receptor T cells     Quality control     Nonclinical research     Safety     Efficacy     Clinical    

HTML PDF Collect

Phase I study of CBM.CD19 chimeric antigen receptor T cell in the treatment of refractory diffuse large

Frontiers of Medicine 2022, Volume 16, Issue 2,   Pages 285-294 doi: 10.1007/s11684-021-0843-8

Abstract: Anti-CD19 chimeric antigen receptor (CAR) T cell therapy has shown impressive efficacy in treating B-cellA single-center phase I dose-escalation study was conducted to evaluate the safety and efficacy of Tcells transduced with CBM.CD19 CAR, a second-generation anti-CD19 CAR bearing 4-1BB costimulatory moleculeTen heavily treated patients with refractory DLBCL were given CBM.CD19 CAR-T cell (C-CAR011) treatmentThe overall response rate was 20% and 50% at 4 and 12 weeks after the infusion of C-CAR011, respectively

Keywords： CAR-T cell therapy     refractory diffuse large B-cell lymphoma     cytokine release syndrome     dose-limiting    

HTML PDF Collect

Engineered T Cell Therapies from a Drug Development Viewpoint Review

Fang Chen, Joseph A. Fraietta, Carl H. June, Zhongwei Xu, J. Joseph Melenhorst, Simon F. Lacey

Engineering 2019, Volume 5, Issue 1,   Pages 140-149 doi: 10.1016/j.eng.2018.11.010

Abstract: For example, T cells can be genetically modified to express chimeric antigen receptors (CARs), endowingAnti-CD19 chimeric antigen receptor T cells (CART19) have demonstrated a remarkable degree of clinicalThis article reviews the use of biomarker-based assays to guide the optimization of CAR constructs, preclinicalAdvanced technologies and computational tools that enable the discovery of optimal targets, novel CARWe believe that the success of CART19 will lead to the development of other engineered T cell therapies

Keywords： Engineered T cell therapies     Chimeric antigen receptor     Drug development process     Biomarkers     CAR19    

HTML PDF Collect

Management of cytokine release syndrome related to CAR-T cell therapy

Hongli Chen, Fangxia Wang, Pengyu Zhang, Yilin Zhang, Yinxia Chen, Xiaohu Fan, Xingmei Cao, Jie Liu, Yun Yang, Baiyan Wang, Bo Lei, Liufang Gu, Ju Bai, Lili Wei, Ruili Zhang, Qiuchuan Zhuang, Wanggang Zhang, Wanhong Zhao, Aili He

Frontiers of Medicine 2019, Volume 13, Issue 5,   Pages 610-617 doi: 10.1007/s11684-019-0714-8

Abstract: Chimeric antigen receptor T (CAR-T) cell therapy is a novel cellular immunotherapy that is widely usedrefractory multiple myeloma and three patients with acute lymphocytic leukemia who suffered CRS during CAR-T

Keywords： chimeric antigen receptor T cell     cytokine release syndrome     tocilizumab    

HTML PDF Collect

Precision medicine in acute lymphoblastic leukemia

Ching-Hon Pui

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 689-700 doi: 10.1007/s11684-020-0759-8

Abstract: and other preclinical methods have identified several high-risk subtypes, such as hypodiplod, early T-cellprecursor, immature T-cell, -rearranged, Ph-positive and -positive ALL, that may respond to BCL-2targetable genetic lesions, current approaches that offer hope include blinatumomab, inotuzumab and CAR-Tcell therapy for B-ALL, and daratumumab and nelarabine for T-ALL.

Keywords： lymphoblastic leukemia     molecular therapeutics     targeted therapy     tyrosine kinase inhibitors     immunotherapy     CART-cell therapy    

HTML PDF Collect

A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma

Houli Zhao, Yiyun Wang, Elaine Tan Su Yin, Kui Zhao, Yongxian Hu, He Huang

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 711-725 doi: 10.1007/s11684-020-0808-3

Abstract: Chimeric antigen receptor T (CAR-T) cells were introduced as a treatment for these patients., clinical data revealed that some patients remained in remission for more than two years after the CAR-TOther than the CD19-targeted CAR-T, the novel target antigens, such as CD20, CD22, CD30, and CD37, whichNonetheless, the CAR-T therapy was usually associated with potentially lethal adverse effects, such asTherefore, optimizing the structure of CAR, creating new drugs, and combining CAR-T cell therapy with

Keywords： chimeric antigen receptor T (CAR-T) cell     lymphoma     cytokine release syndrome (CRS)     immune effector cell-associated    

HTML PDF Collect

The Status and Problems in Developing Private Use Car for China

Guo Konghui

Strategic Study of CAE 2000, Volume 2, Issue 8,   Pages 25-30

Abstract:

Should China develop its private use car? What kind of passenger car should China develop?Should China develop its own passenger car industry?What is the way out for China´s passenger car industry?And how to develop Chinese passenger car industry?to solve the“auto disaster”problems is not to put more restrains on the use of private car

Keywords： Chinese auto industry     private use car     family use car     state and problems    

HTML PDF Collect

Thermal response of steel framing members in open car park fires

Xia YAN; Marion CHARLIER; Thomas GERNAY

Frontiers of Structural and Civil Engineering 2022, Volume 16, Issue 9,   Pages 1071-1088 doi: 10.1007/s11709-022-0879-0

Abstract: For open car park structures, adopting a performance-based structural fire design is often justifiedthis design approach requires an accurate assessment of temperatures in structural members exposed to carThis paper describes a numerical study on the thermal exposure on steel framing members in open car parkResults show that temperatures in unprotected beams and columns are influenced by the section geometry, car

Keywords： open car park     localized fire     steel frame     numerical modeling     computational fluid dynamics    

HTML PDF Collect

Title Author Date Type Operation

CAR T-cell immunotherapy: a powerful weapon for fighting hematological B-cell malignancies

Journal Article

CRISPR-Cas9 mediated LAG-3 disruption in CAR-T cells

Yongping Zhang, Xingying Zhang, Chen Cheng, Wei Mu, Xiaojuan Liu, Na Li, Xiaofei Wei, Xiang Liu, Changqing Xia, Haoyi Wang

Journal Article

Programming CAR T cells to enhance anti-tumor efficacy through remodeling of the immune system

Xiaohui Wang, Zhiqiang Wu, Wei Qiu, Ping Chen, Xiang Xu, Weidong Han

Journal Article

Chimeric antigen receptor T cell therapies for acute myeloid leukemia

Bin Gu, Jianhong Chu, Depei Wu

Journal Article

Chimeric Antigen Receptors and Regulatory T Cells: The Potential for HLA-Specific Immunosuppression in

Sabrina Wright, Conor Hennessy, Joanna Hester, Fadi Issa

Journal Article

CAR T cells redirected against tumor-specific antigen glycoforms: can low-sugar antigens guarantee a

Journal Article

exosomes induce initial activation by exosomal CD19 antigen but impair the function of CD19-specific CART-cells via TGF-β signaling

Journal Article

Quality Control and Nonclinical Research on CAR-T Cell Products: General Principles and Key Issues

Yonghong Li, Yan Huo, Lei Yu, Junzhi Wang

Journal Article

Phase I study of CBM.CD19 chimeric antigen receptor T cell in the treatment of refractory diffuse large

Journal Article

Engineered T Cell Therapies from a Drug Development Viewpoint

Fang Chen, Joseph A. Fraietta, Carl H. June, Zhongwei Xu, J. Joseph Melenhorst, Simon F. Lacey

Journal Article

Management of cytokine release syndrome related to CAR-T cell therapy

Hongli Chen, Fangxia Wang, Pengyu Zhang, Yilin Zhang, Yinxia Chen, Xiaohu Fan, Xingmei Cao, Jie Liu, Yun Yang, Baiyan Wang, Bo Lei, Liufang Gu, Ju Bai, Lili Wei, Ruili Zhang, Qiuchuan Zhuang, Wanggang Zhang, Wanhong Zhao, Aili He

Journal Article

Precision medicine in acute lymphoblastic leukemia

Ching-Hon Pui

Journal Article

A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma

Houli Zhao, Yiyun Wang, Elaine Tan Su Yin, Kui Zhao, Yongxian Hu, He Huang

Journal Article

The Status and Problems in Developing Private Use Car for China

Guo Konghui

Journal Article

Thermal response of steel framing members in open car park fires

Xia YAN; Marion CHARLIER; Thomas GERNAY

Journal Article